Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Northwestern University
Sponsor:
Collaborators:
Robert H. Lurie Cancer Center
National Comprehensive Cancer Network
GlaxoSmithKline
Information provided by (Responsible Party):
Northwestern University
ClinicalTrials.gov Identifier:
NCT01465659
First received: October 4, 2011
Last updated: September 11, 2014
Last verified: September 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: August 2017
  Estimated Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)